Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with ...

Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday.Please watch the video at Investors.com - How To Buy ...

Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The ...

Patient advocates push for generic drug production to treat rare diseases, facing patent barriers and high costs.

From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know ...

Coming off of a strong third quarter, Vertex Pharmaceuticals is nearing several important milestones, including the potential approvals of vanzacaftor triple in cystic fibrosis and the non-opioid ...